


Global Paget's Disease Market Set for Rapid Growth: Key Trends, Drivers, and Opportunities 2025 | DataM Intelligence

The Paget's Disease Market is expected to reach at a Significant CAGR during the forecast period 2024-2031.

AUSTIN, TX, UNITED STATES,
September 2, 2025 /EINPresswire.com/
-- Overview of the Market:

Paget's Disease Market of bone is a chronic skeletal disorder characterized by abnormal bone remodeling, leading to enlarged and weakened bones. This condition primarily affects individuals over the age of 50 and is more prevalent in men than women. The exact cause remains unclear, but genetic and environmental factors are believed to contribute to its development. The disease often progresses slowly and may remain asymptomatic for years, making early diagnosis challenging. When symptoms do occur, they can include bone pain, deformities, and an increased risk of fractures.



DATA INTELLIGENCE

Paget's Disease Market

Significant CAGR

Key players:

- Sun Pharmaceutical Industries Ltd.
- Teva Canada Limited
- Fresenius Kabi AG
- Mylan N.V.
- Novartis AG
- Allergan USA, Inc.
- DAIICHI SANKYO COMPANY, LIMITED.
- Viartis Inc.
- Ajinomoto Co.

Info@datamintelligence.com

Paget's Disease Market

“

The Global Paget's Disease Market is expanding rapidly, driven by rising geriatric population, advanced therapies, and increasing awareness of bone disorder management.”

DataM Intelligence

To Download Sample Report Here:

<https://www.datamintelligence.com/download-sample/pagets-disease-market>

The Global Paget's disease treatment market is projected to experience steady growth over the next decade. The growth is driven by factors such as an aging global population, advancements in treatment modalities, and increasing awareness among healthcare professionals and patients. The North American region currently holds the

largest market share, accounting for about 45% of the total revenue, followed by Europe at 30%. The Asia Pacific region is anticipated to witness the fastest growth, with a projected CAGR of 8%

during the forecast period.

Key Highlights from the Report:

Bisphosphonates remain the preferred treatment, dominating both market share and growth rate due to their high efficacy in treating Paget's disease.

North America contributed approximately 45% to the Paget's disease treatment market in 2023, with Europe following at 30%.

The Asia Pacific region is expected to witness the fastest growth, with a projected CAGR of 8% during the forecast period.

Clinics are the fastest-growing application segment, with a projected CAGR of 7% during the forecast period, driven by increased outpatient care and more accessible treatment options. The market is characterized by the presence of established pharmaceutical companies and ongoing research and development activities.

Market Segmentation:

By Treatment Type

The Paget's disease treatment market is segmented into several categories:

Bisphosphonates: These are the most commonly used drugs for treating Paget's disease. They work by inhibiting osteoclast-mediated bone resorption, thereby controlling bone turnover.

Calcitonin: A hormone that helps regulate calcium levels and bone metabolism. It is used less frequently due to the availability of more effective treatments.

Analgesics: Pain relievers are used to manage bone pain associated with the disease.

Calcium and Vitamin D Supplements: Often prescribed to support bone health and prevent complications.

Surgical Interventions: In cases where there are severe deformities or fractures, surgical procedures may be necessary.

By End-User

Hospitals: Provide comprehensive care, including diagnostics, treatment, and rehabilitation services.

Clinics: Offer outpatient services and are becoming increasingly popular due to their accessibility and convenience.

Homecare Settings: Allow patients to receive treatment in the comfort of their homes, particularly beneficial for elderly individuals.

By Route of Administration

Oral: Includes tablets and capsules, which are convenient and commonly prescribed.

Intravenous (IV): Administered in clinical settings, IV treatments are used for patients who cannot tolerate oral medications.

Topical: Creams and ointments applied directly to the skin can help manage localized pain.

Buy Now & Unlock 360° Market Intelligence: <https://www.datamintelligence.com/buy-now-page?report=pagets-disease-market>

Regional Insights:

North America

North America dominates the Paget's disease treatment market, accounting for approximately 45% of the global revenue in 2023. This is attributed to the high prevalence of the disease in the region, advanced healthcare infrastructure, and significant healthcare expenditure.

Europe

Europe holds the second-largest market share, driven by a well-established healthcare system and increasing awareness about Paget's disease. Countries like the UK, Germany, and France have robust diagnostic and treatment facilities.

Asia Pacific

The Asia Pacific region is expected to witness the fastest growth, with a projected CAGR of 8% during the forecast period. Factors contributing to this growth include a large aging population, improving healthcare infrastructure, and rising healthcare awareness.

Latin America and Middle East & Africa

These regions currently hold smaller market shares but are anticipated to grow steadily due to improving healthcare access and increasing disease awareness.

Market Dynamics:

Market Drivers

Aging Population: The increasing number of elderly individuals worldwide is a significant factor contributing to the rise in Paget's disease cases.

Advancements in Treatment: Innovations in drug development and treatment options have improved patient outcomes and expanded market growth.

Increased Awareness: Rising awareness among healthcare professionals and patients has led to earlier diagnosis and better management of the disease.

Market Restraints

High Treatment Costs: The expense associated with long-term treatment can be a barrier for patients, especially in low-income regions.

Limited Accessibility: In some areas, especially rural regions, access to specialized care and medications is limited.

Side Effects of Treatments: Some treatments may have adverse effects, leading to patient non-compliance.

Market Opportunities

Emerging Markets: Countries in Asia Pacific and Latin America present untapped opportunities due to improving healthcare systems.

Research and Development: Investing in R&D can lead to the development of more effective and affordable treatment options.

Telemedicine: The rise of telehealth services can improve access to care for patients in remote areas.

Frequently Asked Questions (FAQs)

How big is the Paget's disease treatment market?

Who are the key players in the Paget's disease treatment market?

What is the projected growth rate of the Paget's disease treatment market?

What is the market forecast for 2032?

Which region is estimated to dominate the Paget's disease treatment market through the forecast period?

Company Insights:

Sun Pharmaceutical Industries Ltd.

Teva Canada Limited

Fresenius Kabi AG

Mylan N.V.

Novartis AG

Allergan USA, Inc.

DAIICHI SANKYO COMPANY, LIMITED.

Viartis Inc.

Ajinomoto Co.

Pfizer Inc.

Recent Developments:

USA:

August 31, 2025 - Market growing at 14.9% CAGR with increasing adoption of targeted therapies and personalized medicine approaches.

June 24, 2025 - Launch of Calcitonin Salmon Injection by Fresenius Kabi for symptomatic Paget's disease treatment.

Japan:

August 2025 - Growth driven by aging population, tech-savvy healthcare, and precision medicine focus for rare cancer management including Paget's disease.

Growing collaboration between dermatology clinics and academic hospitals with emphasis on minimally invasive surgical techniques.

Unlock 360° Market Intelligence with DataM Subscription Services:

<https://www.datamintelligence.com/reports-subscription>

Conclusion:

The Paget's Disease Treatment Market is poised for steady growth, driven by an aging global population, advancements in treatment options, and increased awareness. While challenges such as high treatment costs and limited accessibility persist, opportunities in emerging markets and ongoing research and development efforts present avenues for expansion. Stakeholders in the healthcare and pharmaceutical sectors should focus on innovation, accessibility, and patient-centered care to capitalize on the market's potential.

Related Reports:

[Meniere's Disease Treatment Market](#)

[Pompe Disease Therapeutics Market](#)

Sai Kiran

DataM Intelligence 4Market Research

+1 877-441-4866

Sai.k@datamintelligence.com

Visit us on social media:

[LinkedIn](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/845316477>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors

try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.